CN108367048B - 用于组织修复的双特异性治疗性蛋白质 - Google Patents

用于组织修复的双特异性治疗性蛋白质 Download PDF

Info

Publication number
CN108367048B
CN108367048B CN201680070850.6A CN201680070850A CN108367048B CN 108367048 B CN108367048 B CN 108367048B CN 201680070850 A CN201680070850 A CN 201680070850A CN 108367048 B CN108367048 B CN 108367048B
Authority
CN
China
Prior art keywords
variant
igf
tissue
seq
bispecific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680070850.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN108367048A (zh
Inventor
L·D·J·安提珀夫
S·艾西吉
K·M·库臣贝克
B·L·米勒德
M·D·昂桑姆
A·D·尼克森
T·R·斯托
Y·张
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Silver Creek Pharmaceuticals Inc
Original Assignee
Silver Creek Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Silver Creek Pharmaceuticals Inc filed Critical Silver Creek Pharmaceuticals Inc
Priority to CN202210868944.5A priority Critical patent/CN115960249A/zh
Publication of CN108367048A publication Critical patent/CN108367048A/zh
Application granted granted Critical
Publication of CN108367048B publication Critical patent/CN108367048B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680070850.6A 2015-10-02 2016-09-30 用于组织修复的双特异性治疗性蛋白质 Active CN108367048B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210868944.5A CN115960249A (zh) 2015-10-02 2016-09-30 用于组织修复的双特异性治疗性蛋白质

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562236169P 2015-10-02 2015-10-02
US62/236,169 2015-10-02
US201562237889P 2015-10-06 2015-10-06
US62/237,889 2015-10-06
US201662322910P 2016-04-15 2016-04-15
US62/322,910 2016-04-15
PCT/US2016/054744 WO2017059231A1 (en) 2015-10-02 2016-09-30 Bi-specific therapeutic proteins for tissue repair

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210868944.5A Division CN115960249A (zh) 2015-10-02 2016-09-30 用于组织修复的双特异性治疗性蛋白质

Publications (2)

Publication Number Publication Date
CN108367048A CN108367048A (zh) 2018-08-03
CN108367048B true CN108367048B (zh) 2022-08-12

Family

ID=58427983

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202210868944.5A Pending CN115960249A (zh) 2015-10-02 2016-09-30 用于组织修复的双特异性治疗性蛋白质
CN201680070850.6A Active CN108367048B (zh) 2015-10-02 2016-09-30 用于组织修复的双特异性治疗性蛋白质

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202210868944.5A Pending CN115960249A (zh) 2015-10-02 2016-09-30 用于组织修复的双特异性治疗性蛋白质

Country Status (7)

Country Link
US (6) US10040840B2 (enExample)
EP (2) EP3865147B1 (enExample)
JP (2) JP7005019B2 (enExample)
CN (2) CN115960249A (enExample)
CA (1) CA3000742A1 (enExample)
ES (1) ES2863278T3 (enExample)
WO (1) WO2017059231A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103124788B (zh) * 2010-05-21 2016-01-13 梅里麦克制药股份有限公司 双特异性融合蛋白
CN115960249A (zh) 2015-10-02 2023-04-14 银溪制药股份有限公司 用于组织修复的双特异性治疗性蛋白质
CN111763680A (zh) * 2019-05-22 2020-10-13 杭州杰迪生物科技有限公司 一种人胰岛素样生长因子-i或其类似物的制备方法、编码基因、表达载体及宿主细胞
JP7355326B2 (ja) * 2019-08-05 2023-10-03 デンカ株式会社 経粘膜投与薬剤
MX2022002638A (es) * 2019-09-06 2022-03-25 Novartis Ag Proteinas de fusion terapeuticas.
CN112584507B (zh) 2019-09-30 2022-05-17 华为技术有限公司 一种数据处理方法、装置及存储介质
WO2021133822A1 (en) 2019-12-24 2021-07-01 Juvena Therapeutics,Inc. Regenerative polypeptides and uses thereof
CN111195350A (zh) * 2020-01-15 2020-05-26 重庆大学 IGF1和IGF1Ec24联合在制备促进组织修复与再生的药物中的应用
AU2021319203A1 (en) * 2020-07-30 2023-03-02 Silver Creek Pharmaceuticals, Inc. Chimeric proteins and methods of use for treatment of central nervous system disorders
US20240141001A1 (en) 2021-06-14 2024-05-02 Institut National de la Santé et de la Recherche Médicale Mutated annexin a5 polypeptides and uses thereof for therapeutic purposes
CA3223707A1 (en) 2021-06-21 2022-12-29 Hanadie Yousef Regenerative polypeptides and uses thereof
EP4363439A4 (en) * 2021-06-30 2025-12-17 Silver Creek Pharmaceuticals Inc Chimeric proteins for the targeted release of growth factors to the glomerulus
WO2023159067A2 (en) * 2022-02-15 2023-08-24 Silver Creek Pharmaceuticals, Inc. Chimeric proteins for treatment of acute radiation syndrome
EP4652192A1 (en) * 2024-03-25 2025-11-26 Cavalry Biosciences, Inc. Igf-1-related compositions and uses of the same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1723219A (zh) * 2003-11-13 2006-01-18 韩美药品工业株式会社 利用免疫球蛋白片段的蛋白质复合物及其制备方法
CN101146826A (zh) * 2005-01-24 2008-03-19 得克萨斯大学体系董事会 与磷脂酰丝氨酸结合的fc融合构建体及其治疗用途
CN103124788A (zh) * 2010-05-21 2013-05-29 梅里麦克制药股份有限公司 双特异性融合蛋白

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL269416A (enExample) 1960-09-21
GB8819826D0 (en) 1988-08-20 1988-09-21 Kabivitrum Ab Glycosylated igf-1
US5679771A (en) 1990-02-13 1997-10-21 Gropep Pty. Ltd. Method for treating intestinal diseases
ATE218889T1 (de) 1990-11-09 2002-06-15 Stephen D Gillies Cytokine immunokonjugate
US5632986A (en) 1991-05-09 1997-05-27 The University Of Washington Phospholipid-targeted thrombolytic agents
US5444045A (en) * 1992-09-17 1995-08-22 Gropep, Pty. Ltd. Method of administering IGF-1, IGF-2, and analogs thereof to birds
WO1995019791A1 (en) * 1994-01-24 1995-07-27 Neorx Corporation Radiolabeled annexins
EP0756494A1 (en) 1994-05-24 1997-02-05 Amgen Boulder Inc. Modified insulin-like growth factors
US5780052A (en) 1995-04-24 1998-07-14 Northeastern University Compositions and methods useful for inhibiting cell death and for delivering an agent into a cell
EP0854884A1 (en) 1996-04-17 1998-07-29 Neurocrine Biosciences, Inc. Ligand inhibitors of insulin-like growth factor binding proteins and methods of use therefor
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
AU750414B2 (en) 1998-07-13 2002-07-18 Board Of Regents, The University Of Texas System Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
US6387663B1 (en) 1998-07-31 2002-05-14 University Of Southern California Targeting pharmaceutical agents to injured tissues
AUPP785098A0 (en) 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
JP2002535967A (ja) 1999-01-06 2002-10-29 ジェネンテック・インコーポレーテッド インシュリン様成長因子（ｉｇｆ）ｉ変異体
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
CA2378925C (en) 1999-07-21 2010-04-06 University Of Southern California Matrix-targeted fusion polypeptides for tissue regeneration and wound healing
JP2001251104A (ja) 2000-03-03 2001-09-14 Murata Mfg Co Ltd 非可逆回路素子及び通信機装置
CA2419561A1 (en) 2000-08-29 2002-03-07 Colorado State University Research Foundation Method for treating the central nervous system by administration of igf structural analogs
UY27087A1 (es) 2001-01-05 2002-06-20 Pfizer Anticuerpos contra el receptor del factor de crecimiento similar a insulina
US7635680B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury
ATE384736T1 (de) 2001-04-30 2008-02-15 Zystor Therapeutics Inc Subzelluläres targeting von therapeutischen proteinen
US7049286B2 (en) 2001-08-30 2006-05-23 Diatos, S.A. Insulin conjugates and methods of use thereof
AU2008200706B2 (en) 2001-10-16 2010-05-27 Biomarin Pharmaceutical Inc. Methods and compositions for targeting underglycosylated proteins across the blood brain barrier
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
WO2003091398A2 (en) 2002-04-23 2003-11-06 Roger Williams Hospital Compositions and methods for stem cell delivery
ATE534658T1 (de) 2002-06-06 2011-12-15 Tze Chein Wun Neue rekombinante antikoagulationsproteine
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US20040213738A1 (en) 2003-03-31 2004-10-28 Susan Croll-Kalish CIRL3-Like proteins, nucleic acids, and methods of modulating CIRL3-L-mediated activity
WO2005033134A2 (en) 2003-09-30 2005-04-14 Regeneron Pharmaceuticals, Inc. Secreted protein therapeutics and uses thereof
CA2565827A1 (en) 2004-05-05 2005-12-15 Merrimack Pharmaceuticals, Inc. Bispecific binding agents for modulating biological activity
WO2006004910A2 (en) 2004-06-28 2006-01-12 Transtarget Inc. Improved bispecific antibodies
US7511016B2 (en) 2004-07-07 2009-03-31 Mosamedix B.V. Annexins, derivatives thereof, and annexin-cys variants, as well as therapeutic and diagnostic uses thereof
JP2008510732A (ja) 2004-08-20 2008-04-10 ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システム 心臓組織の損傷を処置、予防、阻害、または緩和する方法
US7531318B2 (en) 2004-08-20 2009-05-12 Board Of Regents, The University Of Texas System Screening of agents for activity against ischemic myocardial insults
WO2006047214A2 (en) * 2004-10-21 2006-05-04 Igf Oncology, Llc Toxins and radionuclides coupled to igf-1 receptor ligands for treatment of cancer
EP2241575B1 (en) 2005-01-07 2015-06-24 Regeneron Pharmaceuticals, Inc. IGF-1 fusion polypeptides and therapeutic uses thereof
EP1841467A4 (en) 2005-01-14 2009-01-28 Cytogen Corp COMBINATION CANCER THERAPY WITH ANTI-PSMA ANTIBODIES
WO2006091209A2 (en) 2005-02-23 2006-08-31 Merrimack Pharmaceuticals, Inc. Bispecific binding agents for modulating biological activity
US7521211B2 (en) 2005-04-05 2009-04-21 Regeneron Pharmaceuticals, Inc IGF-1 and IGF-2 chimeric polypeptides and therapeutic uses thereof
CA2609728A1 (en) 2005-05-27 2006-11-30 Five Prime Therapeutics, Inc. Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseases
BRPI0614761A2 (pt) 2005-08-12 2009-05-19 Human Genome Sciences Inc proteìnas de fusão de albumina
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
WO2007044887A2 (en) 2005-10-11 2007-04-19 Transtarget, Inc. Method for producing a population of homogenous tetravalent bispecific antibodies
DK1960790T3 (en) 2005-12-12 2017-03-06 Mosamedix Bv ANNEXIN DERIVATIVES SUITABLE FOR PREGNANCY FOR TREATMENT AND DIAGNOSIS
US7776816B2 (en) 2006-01-20 2010-08-17 Board Of Regents, The University Of Texas System Preserving hypoxic tissue
US20080071063A1 (en) 2006-02-03 2008-03-20 Medimmune, Inc. Protein Formulations
AU2007227292B2 (en) 2006-03-17 2012-04-12 Biogen Ma Inc. Stabilized polypeptide compositions
JP2009539805A (ja) 2006-06-09 2009-11-19 ノバルティス アクチエンゲゼルシャフト 安定化されたインスリン様増殖因子ポリペプチド
US9187517B2 (en) 2006-11-13 2015-11-17 The Brigham And Women's Hospital, Inc. Methods of promoting cardiac repair using growth factors fused to heparin binding sequences
SE530073C2 (sv) 2007-01-23 2008-02-26 Teknikbolaget K Samuelsson Ab Sprutmunstycksanordning för brandsläckningssystem
US8003761B2 (en) 2007-01-23 2011-08-23 Hoffmann-La Roche Inc. Cancerous disease modifying antibodies
WO2008124086A2 (en) 2007-04-05 2008-10-16 President And Fellows Of Harvard College Chimeric activators: quantitatively designed protein therapeutics and uses thereof
WO2008151005A2 (en) 2007-05-31 2008-12-11 Transtarget, Inc. Compositions and methods for tissue repair
US20110045007A1 (en) 2007-05-31 2011-02-24 Genmab A/S Fusion or linked proteins with extended half life
ATE502114T1 (de) 2007-06-21 2011-04-15 Univ Muenchen Tech Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität
WO2009030720A2 (en) 2007-09-06 2009-03-12 Novozymes Biopharma Dk A/S Process for producing a recombinant protein
CN102057054B (zh) 2008-04-11 2015-06-10 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
US8927694B2 (en) 2008-11-18 2015-01-06 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
KR20110126644A (ko) * 2009-01-31 2011-11-23 아이쥐에프 온콜로지, 엘엘씨 항암 단백질-백금 결합체
WO2011011071A2 (en) 2009-07-22 2011-01-27 Ipsen Pharma S.A.S. Analogues of insulin-like growth factor-1 (igf-1)
JP5571186B2 (ja) 2009-07-22 2014-08-13 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ ５９位にアミノ酸置換を有するインスリン様増殖因子−１（ｉｇｆ−１）の類似体
CA2777242A1 (en) 2009-10-14 2011-04-21 Merrimack Pharmaceuticals, Inc. Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof
RU2607374C2 (ru) 2009-10-30 2017-01-10 Новозаймс Байофарма Дк А/С Варианты альбумина
AU2010365057B2 (en) 2010-12-08 2016-12-22 Viacyte, Inc. Agents and methods for inhibiting human pluripotent stem cell growth
US20140315817A1 (en) 2011-11-18 2014-10-23 Eleven Biotherapeutics, Inc. Variant serum albumin with improved half-life and other properties
CN104114575B (zh) 2011-12-15 2019-04-09 爱德迪安（北京）生物技术有限公司 具有降血糖作用的化合物、组合物及其用途
WO2014052451A2 (en) 2012-09-26 2014-04-03 Indiana University Research And Technology Corporation Insulin analog dimers
BR112015024758A2 (pt) 2013-03-29 2017-10-24 Merrimack Pharmaceuticals Inc proteínas de fusão de ligação à cartilagem
AU2015204540B2 (en) 2014-01-12 2020-03-19 Igf Oncology, Llc Fusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof
CN115960249A (zh) 2015-10-02 2023-04-14 银溪制药股份有限公司 用于组织修复的双特异性治疗性蛋白质

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1723219A (zh) * 2003-11-13 2006-01-18 韩美药品工业株式会社 利用免疫球蛋白片段的蛋白质复合物及其制备方法
CN101146826A (zh) * 2005-01-24 2008-03-19 得克萨斯大学体系董事会 与磷脂酰丝氨酸结合的fc融合构建体及其治疗用途
CN103124788A (zh) * 2010-05-21 2013-05-29 梅里麦克制药股份有限公司 双特异性融合蛋白

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
融合蛋白药物的研究进展;李磊等;《中国新药杂志》;20150213;第24卷(第3期);266-270 *

Also Published As

Publication number Publication date
US20220162283A1 (en) 2022-05-26
CN108367048A (zh) 2018-08-03
EP3355907B1 (en) 2021-01-20
US11879002B2 (en) 2024-01-23
US20250145682A1 (en) 2025-05-08
CN115960249A (zh) 2023-04-14
US12122819B2 (en) 2024-10-22
US10040840B2 (en) 2018-08-07
CA3000742A1 (en) 2017-04-06
EP3355907A1 (en) 2018-08-08
EP3865147B1 (en) 2025-08-27
WO2017059231A1 (en) 2017-04-06
EP3355907A4 (en) 2019-08-07
US20200207826A1 (en) 2020-07-02
US20220009991A1 (en) 2022-01-13
JP2018538356A (ja) 2018-12-27
EP3865147A1 (en) 2021-08-18
US10633425B2 (en) 2020-04-28
JP2022002528A (ja) 2022-01-11
US20190169258A1 (en) 2019-06-06
ES2863278T3 (es) 2021-10-11
JP7005019B2 (ja) 2022-02-04
US20170096469A1 (en) 2017-04-06
US11155593B2 (en) 2021-10-26
JP7365715B2 (ja) 2023-10-20
HK1258376A1 (en) 2019-11-08

Similar Documents

Publication Publication Date Title
CN108367048B (zh) 用于组织修复的双特异性治疗性蛋白质
US20230322951A1 (en) Bi-Specific Fusion Proteins
JP5702371B2 (ja) Ｍｕｃ１のアンタゴニストを使用した、炎症の阻害
CN105524176B (zh) 双特异性融合蛋白
RU2770698C2 (ru) Способы лечения кальцификации тканей
CN107810195B (zh) 重组丛生蛋白及其在疾病治疗和预防中的应用
TW201200151A (en) Methods and compositions related to reduced MET phosphorylation by leukocyte cell-derived chemotaxin 2 in tumor cells
HK40058660A (en) Bi-specific therapeutic proteins for tissue repair
HK1258376B (en) Bi-specific therapeutic proteins for tissue repair

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant